A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, Meiyu Fang, Xiaoshi Zhang, Zhiguo Luo, Jing Chen, Gang Huang, Peng Zhang, Ying Cheng, Jiwei Liu, Jiyan Liu, Junping Zhang, Di Wu, Yu Chen, Xiaobiao Ma, Hongming Pan, Renbing Jiang, Xinlan Liu, Xiubao Ren, Hongqi Tian, Zhongwei Jia, Jun Guo, Lu Si
Topics & Concepts
Neuroblastoma RAS viral oncogene homologMelanomaMEK inhibitorMedicineMutantDermatologyCancer researchOncologyInternal medicineChemistryCancerMAPK/ERK pathwayKinaseKRASColorectal cancerGeneBiochemistryMelanoma and MAPK PathwaysCutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers